Powei lee

Assistant Manager
BioGend Therapeutics Co., Ltd.

Director, BioGend Therapeutics, Taiwan

RD manager, Exactech Taiwan, Taiwan 

Speech title & Synopsis

Startup of the Year

BioGend Therapeutics was established in July 2016 with a noble vision to be an innovativesolutions provider for holistic medical care to restore bone and joint functions. We arecommitted to develop regenerative orthobiologic products that fulfill unmet clinical needs. Westrive to be a trusted healthcare partner helping people maintain a healthy and active life style.The project management teams at BioGend Therapeutics are led by seasoned productdevelopment managers with team members from different functional areas. Each developmentproject is carefully planned following the phase-gate process for effective and efficientexecution. For highly regulated biomedical devices, the expertise in regulatory affairs and pre-clinical and clinical development is essential in order to gain regulatory approval and to realizethe potential value of innovative bio-technologies. Through the development of innovative bio-orthopaedic products and the establishment of world class GMP processes, we hope to elevateTaiwan's biomedical industry to a new level.

“RevoCart One step-cartilage repair system”

Single-stage autologous cartilage implantation

No in vitro cell culture and 2nd stage surgery 

Clinical-evidence based safety and effectiveness
RevoCart is an autografting processing and transplantation system for use in surgical treatment of chondral or osteochondral defect at the knee. Autologous cartilage tissue is harvested and minimally manipulated intraoperatively for re-implantation and retention by using a bioresorbable scaffold at the site of a cartilage lesion undergoing treatment. RevoCart had been proved to be effective in repairing focal chondral and osteochondral lesion of knee and current commercially available in Taiwan.